Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.

Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Author information

1
University of Virginia Neuro-Oncology Center, Charlottesville, VA 22908-0432, USA. davidschiff@virginia.edu

Abstract

Most grade II and grade III gliomas, as well as the secondary glioblastomas that arise from these tumors, possess point mutations that affect the substrate binding site of isocitrate dehydrogenase. These mutations are essentially unique to gliomas, seem to represent an early step in gliomagenesis, and confer a favorable prognosis.

PMID:
19498431
DOI:
10.1038/nrneurol.2009.57
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center